TG Therapeutics | TGTX - Sales Revenues


TG Therapeutics reported $192.57M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 9.9B 340M Dec/2025
Ardelyx USD 125.21M 14.89M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Bayer EUR 11.44B 1.78B Dec/2025
Biogen USD 2.28B 250M Dec/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Curis USD 1.14M 1.41M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Infinity Pharmaceuticals USD 583K 148K Jun/2023
J&J USD 24.6B 610M Dec/2025
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Novavax USD 147.14M 76.69M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025
Verastem USD 17.54M 7.53M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025